Clinical utility of circulating tumor-associated cells to predict and monitor chemo-response in solid tumors

Autor: Darshana Patil, Sewanti Limaye, Amit Bhatt, Prashant Kumar, Tim Crook, Sanket Patil, Raymond L. Page, Anantbhushan Ranade, Dadasaheb Akolkar, Andrew Gaya
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
Oncology
Male
Cancer Research
Databases
Factual
medicine.medical_treatment
Toxicology
Cohort Studies
0302 clinical medicine
Circulating tumor cell
Neoplasms
Pharmacology (medical)
Prospective Studies
media_common
Aged
80 and over
Non-invasive liquid biopsy
Surveillance
Precision oncology
Middle Aged
Neoplastic Cells
Circulating
Circulating tumor-associated cells: C-TACs
Treatment Outcome
030220 oncology & carcinogenesis
Disease Progression
Original Article
Female
Drug
Subset Analysis
Adult
medicine.medical_specialty
Treatment response
Adolescent
Concordance
media_common.quotation_subject
Antineoplastic Agents
03 medical and health sciences
Young Adult
In vivo
Internal medicine
medicine
Chemotherapy
Humans
Aged
Pharmacology
business.industry
In vitro chemoresponse profiling: CRP
In vitro
030104 developmental biology
Drug Resistance
Neoplasm
business
Zdroj: Cancer Chemotherapy and Pharmacology
ISSN: 1432-0843
0344-5704
Popis: Purpose Selection of cytotoxic chemotherapy agents (CCA) based on pre-treatment evaluation of drug sensitivities is a desirable but unmet goal for personalized anticancer treatment strategies. Prior attempts to correlate in vitro Chemo-Response Profiles (CRP) of tumor explants or Circulating Tumor Cells (CTCs) with clinical outcomes have been largely unsuccessful. Methods We present results from a large cohort (n = 5090, three Arms) of patients with various solid organ tumors, where CRP of Circulating Tumor-Associated Cells (C-TACs) was determined against cancer-specific CCA panels to generate a database of 56,466 unique CRP. Results In Arm 1 (n = 230), 93.7% concordance was observed between CRP of C-TACs and concurrently obtained Tumor tissue Derived Cells (TDCs). In arm 2 (n = 2201, pretreated), resistance of C-TACs to ≥ 1 CCA was observed in 79% of cases. In a blinded subset analysis of 143 pretreated patients with radiologically ascertained disease progression, CRP of C-TACs was 87% concordant with in vivo treatment failure. In Arm 3 (n = 2734, therapy naïve), innate resistance of C-TACs to ≥ 1 CCA was observed in 61% of cases. In a blinded subset analysis of 77 therapy naïve patients, in vitro chemo-sensitivity of C-TACs was concordant with radiologically ascertained treatment response to first line CCA in 97% of cases. Conclusion To our knowledge, this is the first expansive and in-depth study demonstrating that real-time CRP of C-TACs is a viable approach for non-invasive assessment of response to CCA in solid organ cancers.
Databáze: OpenAIRE
Externí odkaz: